Targeting the CSC/EMT antigen Cripto-1 (Cr-1) in the 4T1 model or the xCT protein, also known as SLC7A11, in the 4T1 or TUBO models with a plasmid-based vaccine inhibited tumor growth by about 30–40% and significantly reduced metastatic spread to the lungs [32,33]. Here, SLC7A11 is linked to neoplasm.